Proven Solutions ImprovedSM
Tosk’s mission is to alleviate the painful, debilitating, and potentially fatal side effects of front line cancer therapies and to make certain cancer drugs effective in patients who do not currently benefit from treatment. We are developing a family of what we call CompanionTM drugs that, when administered alongside certain cancer therapies, such as methotrexate, doxorubicin, cisplatin, EGFR inhibitors, and radiation — what we call parent therapies — will significantly improve patient outcomes.
Tosk has patented two new pharmaceutical products and has two other research-stage products in development. The most advanced, TK-90 for mucositis side effect reduction, has recently entered clinical studies in cancer patients. Mucositis is caused by several different cancer therapies that can damage the inner lining of the gastrointestinal tract resulting in painful ulcers and increased risk of infection.
There were 1.7 million new cases of cancer and 600,000 cancer-related deaths in the U. S. last year. This is despite regular media reports of breakthroughs in treatment, such as monoclonal antibodies and immunotherapies, and many billions of dollars spent on cancer research. New approaches may have long-term promise, but the reality is, most cancers are still treated with drugs that are decades old.
Tosk uses two proprietary drug discovery methods to identify potential CompanionTM drugs. Together, we call these methods OMDSM for Optimizing Marketed DrugsSM be-cause they allow us to efficiently screen compounds for their potential to block the ad-verse side effects of prescription drugs, or make certain drugs effective in patients who currently do not benefit from therapy.